Temporal Trends in the Use of Proliferation Signal Inhibitors in Maintenance Heart Transplantation: A Spanish Multicenter Study

González‐Vílchez, Francisco; Almenar, Luís; Arizón, J.M.; Mirabet, Sònia; Delgado, Juan; Molina, B.D.; Gómez, Marta; Paniagua, María; Pérez‐Villa, Félix; Roig, Eulàlia; Prada, José Antonio Vázquez de

doi:10.1016/j.transproceed.2010.07.060

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Everolimus plus a low‐dose CNI has gradually come into use during the past 20 years as a post‐transplant maintenance protocol . Some recent evaluations of everolimus plus a low‐dose CNI‐reduced and CNI‐free everolimus have reported contradictory results …”

Section: Discussionmentioning

confidence: 99%

High‐dose calcineurin inhibitor‐free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia

Lee

Roan

et al. 2017

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

High‐dose calcineurin inhibitor‐free everolimus as a maintenance regimen for heart transplantation may be a risk factor for Pneumocystis pneumonia

Lee

Roan

et al. 2017

Transplant Infectious Dis

View full text Add to dashboard Cite

show abstract

“…Replacing azathioprine by mofetilmycophenolate [16] and calcineurin inhibitors (cyclosporine and tacrolimus) by mTOR inhibitors as maintenance immune suppression reduced the rate of post-transplant malignancies [22]. Use of these proliferation signal (or mTOR) inhibitors such as sirolimus and everolimus have their main advantage as preventive measure, and less as rescue approach [23].…”

Section: Immune Suppressing Regimen As Confoundermentioning

confidence: 99%

Management of Patients with Malignancy before Heart Transplantation

Wilhelm¹

2020

Int. J. Cardiol. Lipidol. Res.

View full text Add to dashboard Cite

Background: Heart transplantation and malignancy connect in several ways. Cancer can be an incidental finding, cancer treatment can also be the cause of end-stage heart failure, for which heart transplantation is necessary or malignancy can occur after transplantation, because of immune suppression.Methods: This is a database search on Web of Science from 2010 on, with the term "heart transplant* AND (cancer OR malignancy)". This resulted in 3767 titles.Results: Eight articles contained sufficient information about survival. In most series, a history of pre-transplant malignancy (PTM) did not affect survival, except for hematologic malignancy or short cancer-free pre-transplant interval. Other patient-related factors were usually more important. The effect of PTM on the rate of post-transplant malignancy followed a comparable pattern. In patients with chemotherapy-related cardiomyopathy, other causes than malignancy were more important.Conclusions: Outcome for heart transplantation in patients with PTM is acceptable in terms of survival, and occurrence post-transplant malignancy. An appropriate PTM-free interval of two to five year seems necessary. Hematologic PTM have a worse outcome. Although the limitations of this review warrant caution with the interpretation of its results, increased post-transplant screening for malignancy and of use of proliferation signal inhibitors, due to their antineoplastic activity, could be cornerstones of the management of these patients.

show abstract